UBS Group Upgrades Insulet (PODD) to Outperform

UBS Group upgraded shares of Insulet (NASDAQ:PODD) from a market perform rating to an outperform rating in a research report report published on Monday, January 8th, The Fly reports.

PODD has been the topic of a number of other reports. Barclays assumed coverage on Insulet in a report on Friday, September 15th. They set an overweight rating and a $65.00 price target on the stock. Jefferies Group lifted their target price on Insulet from $58.00 to $67.00 and gave the stock a buy rating in a report on Friday, November 3rd. Canaccord Genuity raised Insulet from a hold rating to a buy rating and lifted their target price for the stock from $50.00 to $65.00 in a report on Wednesday, November 1st. Zacks Investment Research cut Insulet from a buy rating to a hold rating in a report on Saturday, November 11th. Finally, Leerink Swann reaffirmed an outperform rating and issued a $74.00 target price (up from $65.00) on shares of Insulet in a report on Thursday, October 12th. Eight investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The company has an average rating of Buy and a consensus price target of $62.53.

Shares of Insulet (NASDAQ:PODD) traded down $1.01 during trading on Monday, reaching $75.84. The company had a trading volume of 353,092 shares, compared to its average volume of 538,882. The company has a current ratio of 4.88, a quick ratio of 4.42 and a debt-to-equity ratio of 4.65. The company has a market cap of $4,471.73, a PE ratio of -151.68 and a beta of 1.59. Insulet has a one year low of $38.43 and a one year high of $78.65.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported ($0.04) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.10) by $0.06. The business had revenue of $121.80 million for the quarter, compared to analysts’ expectations of $114.02 million. Insulet had a negative return on equity of 43.85% and a negative net margin of 6.66%. The business’s quarterly revenue was up 28.4% on a year-over-year basis. During the same period last year, the firm earned ($0.05) earnings per share. equities research analysts anticipate that Insulet will post -0.43 EPS for the current fiscal year.

In other Insulet news, Director James C. Mullen bought 2,500 shares of the company’s stock in a transaction on Monday, November 13th. The stock was acquired at an average price of $67.45 per share, for a total transaction of $168,625.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.90% of the stock is owned by insiders.

Several large investors have recently made changes to their positions in the business. FMR LLC raised its stake in shares of Insulet by 0.5% during the second quarter. FMR LLC now owns 8,687,487 shares of the medical instruments supplier’s stock valued at $445,755,000 after acquiring an additional 39,836 shares in the last quarter. Northern Trust Corp raised its stake in shares of Insulet by 3.2% during the second quarter. Northern Trust Corp now owns 777,986 shares of the medical instruments supplier’s stock valued at $39,919,000 after acquiring an additional 24,188 shares in the last quarter. Paulson & CO. Inc. bought a new stake in shares of Insulet during the second quarter valued at approximately $1,283,000. Fox Run Management L.L.C. bought a new stake in shares of Insulet during the third quarter valued at approximately $435,000. Finally, Point72 Asset Management L.P. bought a new stake in shares of Insulet during the third quarter valued at approximately $33,373,000.

ILLEGAL ACTIVITY NOTICE: This article was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/03/insulet-podd-upgraded-by-ubs-group-to-outperform.html.

About Insulet

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

The Fly

Analyst Recommendations for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply